Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00071760 · ClinicalTrials.gov registry record · Phase 2

Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects

A Phase 2 study, sponsored by ViiV Healthcare.

Completed
Registry status
Phase 2
Development phase
59
Enrollment target

NCT00071760 is a Phase 2 study that has completed, run by ViiV Healthcare. The registered enrollment target is 59 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00071760, a Phase 2 study, has completed, sponsored by ViiV Healthcare.

COMPLETED
Registry status
Phase 2
Development phase
59 participants
Enrollment target

Study Summary

This is a 48-week study to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of an investigational regimen including FDA approved HIV drugs in HIV-infected pediatric subjects, ages 4 weeks to \< 2 years old.

Interventions

  • DRUG ritonavir
  • DRUG GW433908

Trial Details

FieldValue
Enrollment Target 59 participants
Start Date 2003-10-23
Est. Completion 2022-03-29
Phase Phase 2

Sponsor

ViiV Healthcare

182 total trials

What the Registry Record Tells You About NCT00071760

The ClinicalTrials.gov registry entry for NCT00071760 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which ritonavir is the first listed.

NCT00071760 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00071760 about?

NCT00071760 is a clinical study titled "Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects". This is a 48-week study to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of an investigational regimen including FDA approved HIV drugs in HIV-infected pediatric subjects, ages 4 weeks to \< 2 years old.

What is the current status of trial NCT00071760?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2003-10-23. Estimated completion is 2022-03-29.

What interventions are being tested in trial NCT00071760?

The interventions under investigation include: ritonavir (DRUG), GW433908 (DRUG).

Who is sponsoring clinical trial NCT00071760?

This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.